<DOC>
	<DOCNO>NCT01037244</DOCNO>
	<brief_summary>Randomized , placebo-controlled , double-blind , parallel design , Phase 3 study evaluate safety efficacy udenafil , orally administer , potent selective inhibitor PDE-5 versus placebo treatment subject erectile dysfunction ( ED ) .</brief_summary>
	<brief_title>Treatment Erectile Dysfunction I</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Male , least 19 year age Stable monogamous relationship least 6 month consent female partner least 19 year age , vaginal intercourse require study activity History ED ( clinically define inability attain maintain erection penis sufficient permit satisfactory sexual intercourse ) least 3 month duration Partner pregnant lactate History newonset symptomatic coronary artery disease within last 3 month history myocardial infarction cardiac surgical procedure within six month Cardiac arrhythmia require antiarrhythmic treatment Symptomatic congestive heart failure Taking nitrate medication form Uncontrolled diabetes ( HbA1c ≥ 13 % ) Hypersensitivity phosphodiesterase type 5 ( PDE5 ) inhibitor Viagra® , Cialis® Levitra® Previously fail respond PDE5 inhibitor Viagra® , Cialis® Levitra®</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>